21 CFR 606Current Good Manufacturing Practice for Blood and Blood Components

21 CFR Part 606 codifies FDA’s current good manufacturing practice for blood and blood components, including source plasma. It addresses the full operational system that underpins blood safety: qualified personnel, suitable facilities, properly maintained equipment, verified supplies and reagents, validated production and process controls, accurate labeling, complete records, and compliant storage and distribution. The standard frames how a donation becomes a labeled, released unit fit for transfusion without compromising safety, purity, or potency.

Part 606 functions alongside product‑specific technical requirements in 21 CFR Part 640 and establishment registration in Part 607. It also interacts with biologics provisions in Part 600 and infectious disease testing and lookback obligations elsewhere in biologics regulations. Collectively, these rules govern blood centers, hospital transfusion services, and plasma collection operations under FDA’s Center for Biologics Evaluation and Research oversight.

Operationally, Part 606 expects SOP‑driven, evidence‑based control of critical steps, including donor suitability assessment, collection, component manufacture, testing, labeling, quarantine and release, storage, distribution, and investigation of deviations. Records must be contemporaneous and retrievable, enabling traceability of each donation, component, and disposition. This system supports credible investigation if an adverse trend or post‑distribution problem arises.

The regulation’s intent is practical: align daily work with the scientific and ethical imperatives of transfusion medicine. When executed correctly, the result is predictable, auditable performance from the donor’s arm to the recipient’s bedside, a concept often described as end‑to‑end or vein-to-vein time.

Part 606 applies to establishments that collect, process, test, store, or distribute blood and blood components, including source plasma collections supporting further manufacture. It also applies to hospital blood banks and transfusion services to the extent they perform regulated activities such as component preparation, compatibility testing, product relabeling, storage, issue, and distribution. Contract laboratories and service providers that perform covered steps for a licensed establishment must meet applicable requirements through defined quality agreements and oversight.

The regulation is activity‑based. If an institution only receives finished components and performs bedside transfusion without altering labeling, storage conditions, or performing compatibility testing, Part 606 obligations are narrower than for a facility that collects, manufactures, and distributes units. Conversely, operations that recruit donors, determine eligibility, collect, separate, and label components are fully in scope and must demonstrate systemwide compliance.

Applicability also hinges on upstream eligibility determinations and downstream distribution. Establishments must define responsibilities for clinical screening, infectious disease testing, quarantine, and release to distribution. Donor screening and testing expectations are anchored in biologics rules and executed through controlled SOPs. A robust donor-eligibility process and documented donor medical history using a standardized donor-risk-assessment-interview are foundational inputs to 606‑compliant manufacturing steps that follow.

Related regulations remain relevant. Part 640 dictates component‑specific criteria such as volumes, temperatures, and dating periods, while Part 607 governs registration and listing. Where establishments also handle human cells, tissues, or cellular and tissue‑based products, separate applicability under Part 1271 must be assessed and addressed through delineated SOPs and training.

Practical compliance begins with written procedures that define who performs each task, how it is performed, and what records prove it happened. The operational flow connects donor assessment, phlebotomy, component manufacturing, infectious disease testing, labeling, storage, quality control, and final issue or distribution. Each transition is controlled by acceptance criteria, in‑process checks, and quarantine and release decisions executed by trained staff.

Facilities and equipment are prepared in advance, with maintenance and calibration current. Supplies and reagents are approved, lot‑qualified, and used within their dating periods. Collection and processing steps are validated to show they consistently meet specifications, and deviations trigger investigation and appropriate disposition. Compatibility testing and final verification steps protect recipients before product issue.

Traceability is continuous. Donation identification numbers, component codes, test results, and disposition decisions are linked to the responsible personnel and timestamps. If a later finding calls a unit into question, the establishment can trace affected lots, notify recipients or consignees as required, and implement corrective actions across procedures and training.

1. Screen and qualify the donor, document medical history, and perform eligibility review.
2. Collect whole blood or source plasma using approved devices and SOPs.
3. Separate components, perform in‑process controls, and place units under quarantine.
4. Conduct required infectious disease testing and quality control checks.
5. Label units with required donor and product information after passing release criteria.
6. Store under controlled temperatures with continuous monitoring and alarms.
7. Perform compatibility testing as applicable, then issue or distribute with full documentation.
8. Retain records and investigate any deviations, complaints, or post‑distribution events.

At every step, identity preservation is essential; maintaining a documented chain-of-identity prevents mix‑ups and supports credible investigations if a unit is later implicated in a safety concern.

Part 606 organizes expectations across operational building blocks. Personnel must be adequate in number and qualified by education, training, and experience, with a responsible head of the establishment accountable for quality oversight. Facilities must be of suitable size and design to prevent mix‑ups and contamination, enabling defined workflows for collection, processing, testing, labeling, storage, and distribution. Equipment must be selected for fitness to use, installed correctly, maintained on schedule, and calibrated against appropriate standards.

Supplies and reagents must be approved before use, properly labeled, and used within their dating period. Production and process controls hinge on written procedures, validated processes, and documented in‑process checks. Labeling must be accurate and complete, reflecting required donor, product, and testing information. Records must be contemporaneous, legible, and retained for prescribed periods to support traceability and regulatory review.

The table below summarizes core subparts and themes commonly referenced during inspections and quality system gap assessments. Establishments map each requirement to specific SOPs, forms, training curricula, and monitoring plans, then verify performance through internal audits and management review.

For system design, trace each clause to concrete evidence such as SOP identifiers, training records, qualification and validation reports, and batch or component records. This requirement‑to‑evidence mapping underpins internal audits, inspection responses, and the integrity of requirements-traceability throughout the establishment.

Part 606 requires records that are accurate, indelible, and retrievable for regulatory review. Establishments must ensure donor files, collection data, component manufacturing records, test results, equipment logs, environmental monitoring, and distribution documentation are complete and linked to specific lots and personnel. Retention periods must satisfy FDA requirements so traceability persists long after disposition.

When electronic systems are used, the electronic records and electronic signatures controls in 21 CFR Part 11 become relevant. This means validated software, secure user access, audit trails, electronic signature controls, and procedural safeguards around system administration and change control. Validation should be risk‑based and fit for intended use, covering configuration, interfaces, data flows, and report integrity.

Data integrity principles apply across paper and electronic media. Original records or true copies must be attributable, legible, contemporaneous, original, and accurate. For hybrid systems, control static documents and dynamic-vs-static-records thoughtfully to avoid uncontrolled printouts or shadow spreadsheets. Ensure disaster recovery, backups, and archival strategies preserve readability across the retention horizon.

Electronic batch and device histories, laboratory information systems, environmental monitoring, and temperature control platforms should produce audit‑ready outputs. Periodic review of user access, audit trails, and exception reports helps detect unauthorized activity or data anomalies. Proceduralized use of certified reference materials and calibrated instruments protects the validity of analytical results tied to release decisions.

Labeling under 606.120 and 606.121 must be accurate and complete. Container labels and tie‑tags identify the donation, component, anticoagulant, volume, ABO/Rh, expiration date, and required testing statements. Revisions or relabeling are controlled, with verification steps to prevent misidentification. Procedures ensure only units meeting release criteria are labeled for issue or distribution.

Storage conditions must be appropriate for each component type, with continuous temperature control and alarms. Quarantine segregates units pending completion of testing, review, and release. Compatibility testing requirements apply where hospitals and transfusion services issue blood to recipients, with documented verification steps prior to transfusion. Distribution records must show consignee information, dates, carrier details, and conditions as needed to confirm cold‑chain integrity.

Traceability is unit‑centric. Each donation and derivative component carries a unique identifier linking it to donor records, testing results, in‑process controls, labeling history, and final disposition. Barcode standards and controlled numbering systems reduce error rates in high‑throughput settings. Serialization and scanning at each handoff provide a defensible chain of custody from receipt through issue.

Modern systems reduce mislabeling risk by pairing identity controls with device integration and enforced workflows. Establishments often adopt serialized-unit-tracking to harmonize donation identifiers with internal manufacturing identifiers, ensuring reconciliation across quarantine, release, distribution, and any post‑distribution investigation.

Part 606 requires prompt investigation and documentation of deviations, nonconformances, and complaints. Investigations must determine root cause, assess product impact, and define corrective and preventive actions. If a post‑distribution event could affect safety, purity, or potency, establishments evaluate scope, notify consignees as appropriate, and, when indicated, initiate a market action consistent with FDA expectations for recalls.

Biological Product Deviation reporting for blood establishments is codified at 21 CFR 606.171. Establishments must report to FDA deviations, unexpected events, or test inaccuracies that occur in their facility or a contract site and that may affect a distributed product’s safety, purity, or potency. Timeliness, completeness, and accurate product traceability are essential to these submissions.

Lookback obligations triggered by later infectious disease findings are addressed in biologics rules outside Part 606 and require prompt record reviews, recipient notifications, and consignee communication. Establishments use structured SOPs for scope determination, documentation, and regulatory communication. For planning and training, see our focused guide on post‑donation findings and notifications in Donor Eligibility Lookback and Deviation Readiness.

Where a recall is necessary, execute documented classification, strategy, and effectiveness checks aligned with FDA practice, then close with CAPA and management review. Digital workflows in Recall Management help coordinate lot scoping, consignee notification, response tracking, and reconciliation, supported by unambiguous component identifiers and distribution records.

Part 606 is one pillar in a broader regulatory architecture for blood and biologics. Part 640 supplies technical requirements for specific components, including volumes, anticoagulants, storage, and dating periods. Part 607 requires registration and listing for blood establishments. Biologics provisions in Part 600 include reporting obligations and testing contexts relevant to transfusion safety.

Adjacent domains may trigger additional requirements. Establishments handling human cells, tissues, or cellular and tissue‑based products should evaluate 21 CFR Part 1271 for donor screening, eligibility, and cGTP expectations that differ from blood rules. Hospitals using medical devices in collection or testing fall under device regulations for those products, while their quality system for blood operations remains anchored in Part 606.

Voluntary consensus standards and accreditation programs reinforce compliance. AABB Standards for Blood Banks and Transfusion Services layer detailed operational requirements, competency assessment norms, and audit practices. Internationally, the EU Blood Directives and guidance from the European Medicines Agency define comparable controls for donor selection, testing, labeling, and hemovigilance in the European context.

Global public health bodies also influence practice. WHO guidance on blood safety informs donor selection, testing, and hemovigilance systems. Establishments that participate in international collaborations often harmonize processes to meet both FDA requirements and partner‑country expectations. If tissue banking overlaps with blood operations, consult 21-cfr-1271 to avoid gaps or duplications in SOPs and training.

FDA inspects blood establishments to assess conformance with Part 606 and related biologics requirements. Inspectors evaluate organizational control, SOP implementation, training and competency, equipment and calibration, supplies and reagent management, production and labeling controls, record completeness, deviation handling, and reporting. They follow the documentation trail from a labeled unit back to donor eligibility and forward to distribution and issue.

Common inspectional observations include incomplete or outdated procedures, inadequate training documentation, missed equipment maintenance or calibration, insufficient in‑process controls, labeling verification gaps, temperature excursions without appropriate evaluation, and weak deviation investigations. Observations may be captured on FDA Form 483 and escalated to Warning Letters if systemic gaps persist or present risk to public health.

Sustained readiness relies on internal audits, management review, metrics that detect drift, and robust CAPA discipline. Establishments should maintain evidence that each 606 requirement is mapped to controlled procedures, training curricula, forms, and records. Periodic risk reviews help prioritize resources toward high‑impact steps such as donor screening, testing, labeling, and final release decisions.

Practical preparation includes mock inspections, document retrieval drills, and role‑based interview practice to ensure staff can explain processes and produce records quickly. Our Inspection Readiness toolkit and guidance on FDA 483 Response support structured preparation, rapid gap remediation, and durable closure plans aligned with FDA expectations.

Implementing Part 606 at scale requires precise procedures, controlled change, and defensible records. V5 Ultimate provides an integrated quality and operations backbone that unites document control, training management, equipment lifecycle oversight, lab quality control, and end‑to‑end traceability. Establishments configure role‑based workflows to enforce SOP steps, capture contemporaneous records, and route exceptions into structured investigations with CAPA, management review, and effectiveness checks.

Calibration and maintenance schedules are automated with alerts and lockouts to prevent use of out‑of‑tolerance instruments. Electronic batch and device histories link donation identifiers to component manufacturing steps, testing results, labeling decisions, and distribution events. Label templates and approval flows reduce mislabeling risk, while temperature monitoring integrations and alarm acknowledgements preserve cold‑chain evidence suitable for regulatory review.

For reporting, V5 assembles complete deviation dossiers, supports biological product deviation timelines, and generates inspection‑ready audit trails. Analytics highlight recurring causes and drift in critical steps such as donor screening, component processing, and release verification, informing continuous improvement and risk‑based resource allocation across sites.